Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma
- PMID: 17928188
- DOI: 10.1016/j.ejso.2007.08.008
Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma
Abstract
Aims: CD4+ CD25+ forkhead box P3 (FOXP3)+ T(reg) accumulate in malignant tumors and negatively regulate anti-tumor immunity. To determine the prognostic value of tumor-infiltrating regulatory T cells (T(reg)), we conducted a retrospective study on 164 patients with hepatocellular carcinoma (HCC) who underwent curative hepatic resection.
Methods: We investigated the number of tumor-infiltrating FOXP3+ T(reg) in formalin-fixed HCC specimens. The number of FOXP3+ T(reg) for each case was calculated as the total number of positive cells per 10 high-power fields (HPF) on light microscopy. Long-term survival rate after resection according to the number of FOXP3+ T(reg) was accessed by univariate and multivariate analyses.
Results: The mean and median numbers of tumor-infiltrating T(reg) were 29.0 and 14 per 10 HPF for FOXP3+ T(reg). The number of FOXP3+ T(reg) was positively correlated with preoperative serum alpha-fetoprotein levels. The disease-free survival rate was significantly lower in patients with high T(reg) counts (> or =14, n=84) than in those with low T(reg) counts (<14, n=80) (13.6% vs. 25.7% at 5 years; P=0.02). By multivariate analysis, the high T(reg) counts, presence of portal vein invasion, and elevation of preoperative aspartate aminotransferase level were independent predictive factors of tumor recurrence.
Conclusions: The high number of tumor-infiltrating T(reg) is an independent predictive factor of tumor recurrence after hepatic resection for HCC.
Similar articles
-
Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.Am J Surg Pathol. 2012 Jul;36(7):980-6. doi: 10.1097/PAS.0b013e31824e9b7c. Am J Surg Pathol. 2012. PMID: 22446942
-
Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma.Cancer. 2005 Jan 15;103(2):299-306. doi: 10.1002/cncr.20798. Cancer. 2005. PMID: 15578688
-
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.Gastroenterology. 2007 Jun;132(7):2328-39. doi: 10.1053/j.gastro.2007.03.102. Epub 2007 Apr 14. Gastroenterology. 2007. PMID: 17570208
-
[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German.
-
Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39. Arch Surg. 2008. PMID: 18283144 Review.
Cited by
-
Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram.Breast Cancer (Dove Med Press). 2024 Oct 21;16:705-723. doi: 10.2147/BCTT.S484055. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39464238 Free PMC article.
-
Establishment and validation of a cholesterol metabolism-related prognostic signature for hepatocellular carcinoma.Comput Struct Biotechnol J. 2022 Aug 1;20:4402-4414. doi: 10.1016/j.csbj.2022.07.030. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 36051877 Free PMC article.
-
PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045820. doi: 10.1177/15330338211045820. Technol Cancer Res Treat. 2021. PMID: 34605709 Free PMC article. Clinical Trial.
-
NTF3 Correlates With Prognosis and Immune Infiltration in Hepatocellular Carcinoma.Front Med (Lausanne). 2021 Dec 6;8:795849. doi: 10.3389/fmed.2021.795849. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34938753 Free PMC article.
-
Therapeutic targeting of regulatory T cells in cancer.Trends Cancer. 2022 Nov;8(11):944-961. doi: 10.1016/j.trecan.2022.06.008. Epub 2022 Jul 16. Trends Cancer. 2022. PMID: 35853825 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials